What is xCures?
xCures operates at the intersection of artificial intelligence and oncology, providing a sophisticated platform designed to optimize patient outcomes through adaptive treatment planning. The company's core value proposition lies in its ability to retrieve, organize, and structure complex, fragmented medical records into a unified, decision-ready format. By deploying a 'Virtual Tumor Board,' xCures enables healthcare providers to coordinate treatment regimens across entire patient populations, effectively turning every clinical encounter into a learning opportunity. This methodology not only enhances individual care but also accelerates the collective understanding of treatment efficacy, positioning xCures as a critical infrastructure provider for modern, data-centric healthcare organizations.
How much funding has xCures raised?
xCures has raised a total of $58.7M across 2 funding rounds:
Series A
$12.7M
Series B
$46M
Series A (2021): $12.7M with participation from Vanedge Capital and Boehringer Ingelheim Venture Fund
Series B (2026): $46M led by Spring Mountain Capital and Innovius Capital
Key Investors in xCures
Spring Mountain Capital
Spring Mountain Capital specializes in growth equity and private capital, providing essential expansion financing for enterprise technology and healthcare companies across North America.
Innovius Capital
Innovius Venture Capital focuses on supporting SaaS and AI founders during Series A and B stages by embedding go-to-market specialists to accelerate operational growth.
Vanedge Capital
Vanedge Capital is an early-stage venture fund that empowers visionary technologists in the Hard Tech and AI & Analytics sectors, focusing on mitigating execution risk for high-growth companies.
What's next for xCures?
With this latest infusion of capital, xCures is well-positioned to accelerate its go-to-market strategy and deepen its penetration within the enterprise healthcare sector. The company is expected to focus on scaling its AI-driven platform to accommodate larger datasets and more complex clinical environments, thereby solidifying its role in the future of decentralized clinical trials. By continuing to bridge the gap between raw medical data and clinical decision-making, xCures is set to redefine the standards of care, potentially attracting further institutional interest as it matures into a foundational player in the health-tech ecosystem.
See full xCures company page
